ICT 140

Drug Profile

ICT 140

Alternative Names: ICT-140

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ovarian cancer

Most Recent Events

  • 26 Jul 2016 ICT 140 is still in preclinical phase for Ovarian cancer in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
  • 29 Jan 2013 US FDA approves IND application for ICT 140 in Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top